Silence Therapeutics plc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
SLN$19.79+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| Year ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Net Loss | $(45,309) | $(54,228) | $(50,334) |
| Other comprehensive income (loss): | |||
| Foreign exchange differences arising on consolidation of foreign operations (net of tax) | (1,055) | 789 | (86) |
| Total other comprehensive (loss)/income for the year | (1,055) | 789 | (86) |
| Total comprehensive loss for the year | $(46,364) | $(53,439) | $(50,420) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.